Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US6177401A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 9, 1994 |
| Grant date | Jan 23, 2001 |
| Priority date | — |
| Expiry date | Feb 9, 2014 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of proteins, peptides and organic molecules capable of modulating Flk-1 receptor signal transduction in order to inhibit or promote angiogenesis and vasculogenesis. The invention is based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.